Exodus Point Capital Management, LP Apellis Pharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$38.07 - $59.71 $1.26 Million - $1.97 Million	33,013 Added 82.29%	73,133 $2.81 Million
Q1 2024 May 14, 2024	BUY	$55.39 - $72.47 $2.22 Million - $2.91 Million	40,120 New	40,120 $2.36 Million
Q2 2023 Aug 10, 2023	BUY	$76.68 - $93.31 $775,924 - $944,203	10,119 Added 43.87%	33,187 $3.02 Million
Q1 2023 May 11, 2023	BUY	$46.59 - $66.96 $385,578 - $554,160	8,276 Added 55.95%	23,068 $1.52 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $639,606 - $902,903	14,792 New	14,792 $765,000
Q1 2022 May 13, 2022	SELL	$35.46 - $54.12 $494,276 - $754,378	-13,939 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$30.74 - $49.16 $428,484 - $685,241	13,939 New	13,939 $659,000
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $314,000 - $698,400	-10,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $409,000 - $649,000	10,000 New	10,000 $632,000
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $475,890 - $884,083	-15,456 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$25.89 - $33.65 $400,155 - $520,094	15,456 New	15,456 $466,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.